Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Dec;16(6):781–787. doi: 10.1128/aac.16.6.781

Effects of Interferon and Adenine Arabinoside Treatment of Hepatitis B Virus Infection on Cellular Immune Responses

Barry Hafkin 1, Richard B Pollard 1, Moti L Tiku 1, William S Robinson 1, Thomas C Merigan 1
PMCID: PMC352953  PMID: 533259

Abstract

Fifteen patients with chronic hepatitis B were treated with adenine arabinoside (Ara-A) or human leukocyte interferon (HLI). Cellular immune response to hepatitis B virus surface antigen and antigens prepared from herpes simplex virus, varicella zoster virus, and cytomegalovirus was measured by a lymphocyte blast transformation assay and an assay for interferon production. Measurements were made before, during, and after antiviral treatment. Unlike patients convalescing from acute hepatitis B, only 2 of 15 patients with chronic hepatitis B had significant blast transformation to hepatitis B surface antigen. One such response occurred during the pretreatment period of HLI therapy, and the other was in a patient undergoing low-dose (<105 U/kg per day) HLI therapy. Mononuclear cell cultures were tested for interferon production in the presence of hepatitis B surface antigen. Cells from only 1 of 15 patients produced detectable levels of interferon. In contrast, all of these patients had normal cellular immune responses to herpesvirus antigens. Transformation responses to herpes antigens decreased three- to fivefold after patients were treated with >105 U of HLI per kg per day. Antiviral therapy with <105 U of HLI per kg per day or Ara-A did not produce a detectable depression of transformation response. Ara-A produced marked lymphocytopenia and a marked lymphocyte fragility after 5 or more days of therapy. In vitro Ara-A was toxic to lymphocytes at concentrations as low as 0.5 μg/ml. These changes in lymphocyte parameters may affect the outcome of antiviral therapy.

Full text

PDF
781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti A., Realdi G., Bortolotti F., Rigoli A. M. T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection. Gut. 1977 Dec;18(12):1004–1009. doi: 10.1136/gut.18.12.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aldershvile J., Dietrichson O., Hardt F., Nielsen J. O., Skinhöj P. Humoral and cell-mediated immunity to hepatitis B virus antigens in acute and chronic liver disease. Scand J Gastroenterol. 1977;12(8):917–922. doi: 10.3109/00365527709181350. [DOI] [PubMed] [Google Scholar]
  3. Arvin A. M., Pollard R. B., Rasmussen L. E., Merigan T. C. Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis. 1978 May;137(5):531–540. doi: 10.1093/infdis/137.5.531. [DOI] [PubMed] [Google Scholar]
  4. Brodeur B. R., Merigan T. C. Mechanism of the suppressive effect of interferon on antibody synthesis in vivo. J Immunol. 1975 Apr;114(4):1323–1328. [PubMed] [Google Scholar]
  5. Chester T. J., Paucker K., Merigan T. C. Suppression of mouse antibody producing spleen cells by various interferon preparations. Nature. 1973 Nov 9;246(5428):92–94. doi: 10.1038/246092a0. [DOI] [PubMed] [Google Scholar]
  6. De Maeyer E., De Maeyer-Guignard J., Vandeputte M. Inhibition by interferon of delayed-type hypersensitivity in the mouse. Proc Natl Acad Sci U S A. 1975 May;72(5):1753–1757. doi: 10.1073/pnas.72.5.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dudley F. J., Giustino V., Sherlock S. Cell-mediated immunity in patients positive for hepatitis-associated antigen. Br Med J. 1972 Dec 30;4(5843):754–756. doi: 10.1136/bmj.4.5843.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edgington T. S., Chisari F. V. Immunological aspects of hepatitis B virus infection. Am J Med Sci. 1975 Sep-Oct;270(2):212–227. [PubMed] [Google Scholar]
  9. Gisler R. H., Lindahl P., Gresser I. Effects of interferon on antibody synthesis in vitro. J Immunol. 1974 Aug;113(2):438–444. [PubMed] [Google Scholar]
  10. Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976 Sep 2;295(10):517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  11. Haahr S., Rasmussen L., Merigan T. C. Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun. 1976 Jul;14(1):47–54. doi: 10.1128/iai.14.1.47-54.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ibrahim A. B., Vyas G. N., Perkins H. A. Immune response to hepatitis B surface antigen. Infect Immun. 1975 Jan;11(1):137–141. doi: 10.1128/iai.11.1.137-141.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Johnson H. M., Smith B. G., Baron S. Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol. 1975 Jan;114(1 Pt 2):403–409. [PubMed] [Google Scholar]
  14. Lee W. M., Reed W. D., Mitchell C. G., Woolf I. L., Dymock I. W., Eddleston A. L., Williams R. Cell-mediated immunity to hepatitis B surface antigen in blood donors with persistent antigenaemia. Gut. 1975 Jun;16(6):416–420. doi: 10.1136/gut.16.6.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lindahl-Magnusson P., Leary P., Gresser I. Interferon inhibits DNA synthesis induced in mouse lymphocyte suspensions by phytohaemagglutinin or by allogeneic cells. Nat New Biol. 1972 May 24;237(73):120–121. doi: 10.1038/newbio237120a0. [DOI] [PubMed] [Google Scholar]
  16. Merigan T. C. Pharmacokinetics and side effects of interferon in man. Tex Rep Biol Med. 1977;35:541–547. [PubMed] [Google Scholar]
  17. Mistretta A. P., Golferini A., Tassi G. C., De Barbierri A. Identification of some HBAg (HAA) antigenic determinants by two-dimensional electro-immunodiffusion. J Biol Stand. 1974 Oct;2(4):313–318. doi: 10.1016/0092-1157(74)90040-7. [DOI] [PubMed] [Google Scholar]
  18. Pollard R. B., Rand K. H., Arvin A. M., Merigan T. C. Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis. 1978 May;137(5):541–549. doi: 10.1093/infdis/137.5.541. [DOI] [PubMed] [Google Scholar]
  19. Pollard R. B., Smith J. L., Neal A., Gregory P. B., Merigan T. C., Robinson W. S. Effect of vidarabine on chronic hepatitis B virus infection. JAMA. 1978 Apr 21;239(16):1648–1650. [PubMed] [Google Scholar]
  20. Purcell R. H., Holland P. V., Walsh J. H., Wong D. C., Morrow A. G., Chanock R. M. A complement-fixation test for measuring Australia antigen and antibody. J Infect Dis. 1969 Sep;120(3):383–386. doi: 10.1093/infdis/120.3.383. [DOI] [PubMed] [Google Scholar]
  21. Steele R. W., Chapa I. A., Vincent M. M., Hensen S. A., Keeney R. E. Effects of adenine arabinoside on cellular immune mechanisms in humans. Antimicrob Agents Chemother. 1975 Feb;7(2):203–207. doi: 10.1128/aac.7.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tiku M. L., Beutner K. R., Tiku K., Ogra P. L. Cell-mediated immune response to liver tissue antigen and hepatitis B surface antigen after infection with hepatitis B virus in humans. J Infect Dis. 1978 Nov;138(5):587–596. doi: 10.1093/infdis/138.5.587. [DOI] [PubMed] [Google Scholar]
  23. Tong M. J., Wallace A. M., Peters R. L., Reynolds T. B. Lymphocyte stimulation in hepatitis B infections. N Engl J Med. 1975 Aug 14;293(7):318–322. doi: 10.1056/NEJM197508142930702. [DOI] [PubMed] [Google Scholar]
  24. Weinstein Y., Brodeur B. R., Melmon K. L., Merigan T. C. Interferon inhibition of lymphocyte mitogenesis. Immunology. 1977 Sep;33(3):313–319. [PMC free article] [PubMed] [Google Scholar]
  25. de Moura M. C., Vernace S. J., Paronetto F. Cell-mediated immune reactivity to hepatitis B surface antigen in liver diseases. Gastroenterology. 1975 Aug;69(2):310–317. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES